Hypotension News and Research

RSS
Nonmotor features may predict PD progression

Nonmotor features may predict PD progression

The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

Phase 3 study shows Vectibix meets primary endpoint in patients with chemorefractory wild-type KRAS mCRC

Phase 3 study shows Vectibix meets primary endpoint in patients with chemorefractory wild-type KRAS mCRC

Amgen starts Phase 3 study assessing the benefit of Kyprolis in patients with relapsed/refractory multiple myeloma

Amgen starts Phase 3 study assessing the benefit of Kyprolis in patients with relapsed/refractory multiple myeloma

Updated data from PROCLAIM national patient registry presented at 51st ASCO

Updated data from PROCLAIM national patient registry presented at 51st ASCO

RPCI-led research team to share clinical results of entolimod drug at ASCO 2015

RPCI-led research team to share clinical results of entolimod drug at ASCO 2015

Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

UCB sponsoring several presentations on Cimzia for Crohn's disease at DDW 2015

UCB sponsoring several presentations on Cimzia for Crohn's disease at DDW 2015

Lilly receives fourth FDA approval for CYRAMZA (ramucirumab)

Lilly receives fourth FDA approval for CYRAMZA (ramucirumab)

Hospira announces availability of INFLECTRA (infliximab) in Canada

Hospira announces availability of INFLECTRA (infliximab) in Canada

Amgen receives FDA priority review designation for Kyprolis to treat relapsed multiple myeloma

Amgen receives FDA priority review designation for Kyprolis to treat relapsed multiple myeloma

Egalet announces plans to commercialize SPRIX Nasal Spray and OXAYDO tablets

Egalet announces plans to commercialize SPRIX Nasal Spray and OXAYDO tablets

New global study on Acute Kidney Injury (AKI) shows the way to eliminating preventable deaths by 2025 – early detection and management are key

New global study on Acute Kidney Injury (AKI) shows the way to eliminating preventable deaths by 2025 – early detection and management are key

Egalet announces net revenues of $1.9 million for 2014

Egalet announces net revenues of $1.9 million for 2014

United Therapeutics announces FDA approval of dinutuximab for treatment of high-risk neuroblastoma

United Therapeutics announces FDA approval of dinutuximab for treatment of high-risk neuroblastoma

FDA approves Astellas' CRESEMBA for treatment of invasive aspergillosis, invasive mucormycosis

FDA approves Astellas' CRESEMBA for treatment of invasive aspergillosis, invasive mucormycosis

Jazz Pharmaceuticals to present defibrotide results for hepatic VOD at BMT Tandem meetings

Jazz Pharmaceuticals to present defibrotide results for hepatic VOD at BMT Tandem meetings

Kaleo, CHMI partner to reduce prescription drug-related deaths

Kaleo, CHMI partner to reduce prescription drug-related deaths

FDA approves RYTARY for Parkinson's disease treatment

FDA approves RYTARY for Parkinson's disease treatment

Lilly receives FDA approval for CYRAMZA (ramucirumab)

Lilly receives FDA approval for CYRAMZA (ramucirumab)